905306-05-0

Basic information

• Product Name: 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol
• Synonyms: 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol
• CAS NO: 905306-05-0
• Molecular Weight: 291.309
• Mol File: 905306-05-0.mol
• Article Data: 19

Chemical Properties

• Melting Point: 252-254 °C
• Boiling Point: 491.9±45.0 °C(Predicted)
• Density: 1.36±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol(905306-05-0)
• EPA Substance Registry System: 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol(905306-05-0)

Safety Data

• Hazardous Substances Data: 905306-05-0(Hazardous Substances Data)

Upstream product

• 1012057-17-8 4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yl acetate hydrochloride 
• 179688-54-1 4-chloro-7-methoxyquinazolin-6-yl acetate hydrochloride salt 
• 54060-30-9 3-acetylenephenylamine 
• 31839-20-0 5-hydroxy-4-methoxy-2-nitrobenzoic acid 
• 31839-21-1 2-amino-5-hydroxy-4-methoxybenzoic acid 
• 179688-52-9 4,6-dihydroxy-7-methoxyquinazoline 
• 179688-53-0 (4-hydroxy-7-methoxyquinazolin-6-yl) acetate 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 26759-46-6 methyl 2-amino-4,5-dimethoxybenzoate 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 93-07-2 Veratric acid 
• 3943-77-9 ethyl veratrate 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 

Downstream Products

• 1012057-21-4 ethyl 6-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)heptanoate 
• 1165931-38-3 2-butyl-4-chloro-1-{3-[4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy]propyl}-1H-imidazole-5-carboxaldehyde 
• 1214998-21-6 ethyl 5-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)pentanoate 
• 1259519-61-3 N-(3-ethynylphenyl)-7-methoxy-6-(2-methoxyethoxy)quinazolin-4-amine 
• 1259519-22-6 N-(3-ethynylphenyl)-7-methoxy-6-(2-methoxy-d3-ethoxy)quinazolin-4-amine 
• 1389355-15-0 C₁₉H₁₆FN₃O₂ 
• 1389355-29-6 N-(3-ethynylphenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 936446-61-6 NRC-2694 

Relevant articles and documents

Dual nicotinamide phosphoribosyltransferase and epidermal growth factor receptor inhibitors for the treatment of cancer

Multitarget drugs have emerged as a promising treatment modality in modern anticancer therapy. Taking advantage of the synergy of NAMPT and EGFR inhibition, we have developed the first compounds that serve as dual inhibitors of NAMPT and EGFR. On the basis of CHS828 and erlotinib, a series of hybrid molecules were successfully designed and synthesized by merging of the pharmacophores. Among the compounds that were synthesized, compound 28 showed good NAMPT and EGFR inhibition, and excellent in vitro anti-proliferative activity. Compound 28, which is a new chemotype devoid of a Michael receptor, strongly inhibited the proliferation of several cancer cell lines, including H1975 non-small cell lung cancer cells harboring the EGFRL858R/T790M mutation. More importantly, it imparted significant in vivo antitumor efficacy in a human NSCLC (H1975) xenograft nude mouse model. This study provides promising leads for the development of novel antitumor agents and valuable pharmacological probes for the assessment of dual inhibition in NAMPT and EGFR pathway with a single inhibitor.

AN IMPROVED PROCESS FOR THE PREPARATION OF N-(3-ETHYNYLPHENYL)-7-METHOXY-6-(3-MORPHOLINOPROPOXY) QUINAZOLIN -4-AMINE DIHYDROCHLORIDE

Present invention relates to an improved process for the preparation of N-(3- ethynylphenyl)-7-methoxy-6-(3-morpholinopropoxy) quinazolin-4-amine dihydrochloride of formula-I.

Benzo nitrogen hetero-aromatic ring compound, and preparation method and applications thereof

The invention belongs to the field of chemical medicine, and discloses a benzo nitrogen hetero-aromatic ring compound represented by formula I, or pharmaceutically acceptable salts, stereisomers, racemic compounds, prodrugs, or solvates thereof. The invention also discloses applications of the benzo nitrogen hetero-aromatic ring compound in preparation of drugs used for treating diseases caused byprotein kinase and/or nicotinamide phosphoribosyltransferase abnormal activity. The benzo nitrogen hetero-aromatic ring compound represented by formula I or the salts thereof possess tyrosine kinaseand Nampt double inhibition effects, can be taken as effective components in treatment or prevention of tumor, are excellent in curative effect, and low in toxic or side effect.